Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD7-targeted CAR-T cells (Donghua Zhang)
- Development stage
- Unknown
- Lead developer
- Gracell Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD7-targeted CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD7 protein, which is highly expressed in various T-cell malignancies and some myeloid leukemias. Developed as part of an investigator-initiated trial (IIT) led by Donghua Zhang, these T cells are genetically modified to express a CAR that recognizes and binds to CD7-positive tumor cells, triggering T-cell activation and subsequent tumor cell destruction. The therapy is primarily being evaluated for the treatment of relapsed or refractory (r/r) CD7-positive hematological malignancies, including acute T-lymphoblastic leukemia (T-ALL), T-lymphoblastic lymphoma (T-LBL), and acute myeloid leukemia (AML).
- Other names
- CD7-targeted chimeric antigen receptor gene-modified T cellsCD-7-targeted chimeric antigen receptor gene-modified T cellsCD 7-targeted chimeric antigen receptor gene-modified T cellsCD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological MalignanciesCD7 CAR-T cellsCD-7 CAR-T cellsCD 7 CAR-T cells
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on CD7-targeted CAR-T cells (Donghua Zhang).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD7-targeted CAR-T cells (Donghua Zhang).